^
    13d
    Integrative bioinformatics and molecular simulations identify HMGB3 as a key immune modulator in triple negative breast cancer. (PubMed, Discov Oncol)
    This work identifies HMGB3 as a promising immunotherapeutic target in the MLIA subtype of TNBC and highlights Pimicotinib, CID17584963, and CID1763476 as potential HMGB3 inhibitors for drug repurposing strategies.
    Journal
    |
    NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) • MIR214 (MicroRNA 214)
    |
    pimicotinib (ABSK021)
    27d
    Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER) (clinicaltrials.gov)
    P2, N=20, Recruiting, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Not yet recruiting --> Recruiting
    Enrollment open
    |
    pimicotinib (ABSK021)
    1m
    Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER) (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
    New P2 trial
    |
    pimicotinib (ABSK021)
    6ms
    A Study to Evaluate the Relative Bioavailability of Pimicotinib Capsules Containing Free Base in Different Proportions in Healthy Subjects (clinicaltrials.gov)
    P1, N=20, Completed, Abbisko Therapeutics Co, Ltd | Active, not recruiting --> Completed
    Trial completion
    |
    pimicotinib (ABSK021)
    7ms
    A Study to Evaluate the Relative Bioavailability of Pimicotinib Capsules Containing Free Base in Different Proportions in Healthy Subjects (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Abbisko Therapeutics Co, Ltd
    New P1 trial
    |
    pimicotinib (ABSK021)
    8ms
    Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) (clinicaltrials.gov)
    P3, N=90, Active, not recruiting, Abbisko Therapeutics Co, Ltd | Trial primary completion date: May 2026 --> Sep 2024
    Trial primary completion date
    |
    pimicotinib (ABSK021)
    9ms
    Pharmacologic inhibition of CSF-1R suppresses intrinsic tumor cell growth in osteosarcoma with CSF-1R overexpression. (PubMed, J Transl Med)
    These findings conclusively demonstrated that pharmacological inhibition of CSF-1R activity by ABSK021 resulted in significant anti-tumor effects in preclinical osteosarcoma models with CSF-1R overexpression. The high prevalence of CSF-1R expression observed in osteosarcoma patient samples highlights the potential clinical use of ABSK021, either as a monotherapy or in combination with chemotherapy, as a promising therapeutic strategy for osteosarcoma patients with CSF-1R as a potential predictive biomarker.
    Journal
    |
    CASP3 (Caspase 3) • CSF1R (Colony stimulating factor 1 receptor)
    |
    Conmana (icotinib) • pimicotinib (ABSK021)
    11ms
    ABSK021-110: A Study to Investigate The Effect of Pimicotinib on The Pharmacokinetics of Metformin, Fexofenadine and Rosuvastatin In Healthy Subjects (clinicaltrials.gov)
    P1, N=39, Completed, Abbisko Therapeutics Co, Ltd | Active, not recruiting --> Completed
    Trial completion
    |
    metformin • pimicotinib (ABSK021)
    12ms
    ABSK021-101: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=276, Recruiting, Abbisko Therapeutics Co, Ltd | N=85 --> 276 | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    pimicotinib (ABSK021)
    1year
    A Study to Evaluate the Effect of a High-fat Meal on the Exposure of Pimicotinib Capsule in Healthy Subjects (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, Abbisko Therapeutics Co, Ltd | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    pimicotinib (ABSK021)
    1year
    ABSK021-110: A Study to Investigate the Effect of Pimicotinib on the Pharmacokinetics of Metformin, Fexofenadine and Rosuvastatin in Healthy Subjects (clinicaltrials.gov)
    P1, N=38, Active, not recruiting, Abbisko Therapeutics Co, Ltd | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    metformin • pimicotinib (ABSK021)
    1year
    A Study to Evaluate the Effect of a High-fat Meal on the Exposure of Pimicotinib Capsule in Healthy Subjects (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, Abbisko Therapeutics Co, Ltd
    New P1 trial
    |
    pimicotinib (ABSK021)